3SBio Inc. (TRSBF)

Market Cap	2.74B
Revenue (ttm)	1.16B
Net Income (ttm)	228.24M
Shares Out	n/a
EPS (ttm)	0.09
PE Ratio	11.99
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	313
Average Volume	n/a
Open	0.828
Previous Close	0.828
Day's Range	0.828 - 0.828
52-Week Range	0.723 - 0.828
Beta	0.71
RSI	99.73
Earnings Date	Mar 21, 2025

About 3SBio

3SBio Inc., an investment holding company, develops, produces markets, and sells biopharmaceutical products in Mainland China and internationally. The company provides TPIAO, a recombinant human thrombopoietin to treat chemotherapy-induced thrombopenia and immune thrombocytopenia; Cipterbin, an anti-HER2 monoclonal antibody for the treatment of HER2-positive metastatic breast cancer; TNF, pre-filled aqueous injection solution. It also offers YISAIPU, the receptor fusion tumor necrosis factor inhibitor; Mandi-minoxidil tincture, an OTC external ...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1993
• Employees: 5,411
• Stock Exchange: OTCMKTS
• Ticker Symbol: TRSBF

Financial Performance

In 2023, 3SBio's revenue was 7.82 billion, an increase of 13.84% compared to the previous year's 6.87 billion. Earnings were 1.55 billion, a decrease of -19.13%.

Financial numbers in CNY